Evidence map›Paper›PMID 26600305›Full record

ArticleAmerican journal of respiratory cell and molecular biology2016

Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion.

Neil Ahluwalia, Paula E Grasberger, Brian M Mugo, Carol Feghali-Bostwick, Annie Pardo, Moisés Selman, David Lagares, Andrew M Tager

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. The concept of Sfrp1The European respiratory journal · 2024
    Article
  2. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Neil Ahluwalia1 Division of Pulmonary and Critical Care Medicine and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6262-401X
Paula E Grasberger1 Division of Pulmonary and Critical Care Medicine and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Brian M Mugo1 Division of Pulmonary and Critical Care Medicine and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Carol Feghali-Bostwick2 Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina.
Annie Pardo3 Universidad Nacional Autónoma de México, Mexico City, Mexico; and.
Moisés Selman4 Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
David Lagares1 Division of Pulmonary and Critical Care Medicine and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Andrew M Tager1 Division of Pulmonary and Critical Care Medicine and the Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5826-918X
Harvard University · USInstituto Nacional de Enfermedades Respiratorias · MXMedical University of South Carolina · USUniversidad Nacional Autónoma de México · MX

Funding

Research Training in Pulmonary Immunology and Allergy at MGHT32HL116275 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David C Christiani, ANDREW D LUSTER · 2013 to 2026
$8.6M
Rheumatic Diseases Research Core CentersP30AR061271 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITFIELD, MICHAEL L · 2011 to 2015
$3.1M
Protective Role of the S1P-S1P1 Pathway in Pulmonary FibrosisR01HL108975 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TAGER, ANDREW M · 2011 to 2015
$1.8M
Scleroderma Twin Study and analysis of Estrogen in patients with dcSScK24AR060297 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FEGHALI-BOSTWICK, CAROL A. · 2013 to 2025
$1.4M
The LPA Pathway in Lung Fibrosis: Novel Mediators and New Therapeutic TargetsR01HL095732 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI TAGER, ANDREW M · 2009 to 2010
$922k
NHLBI NIH HHS R01 HL095732NHLBI NIH HHS R01 HL108975NHLBI NIH HHS T32 HL116275NIAMS NIH HHS K24 AR060297NIAMS NIH HHS P30 AR061271
6 · The paper itself

Abstract

Pathologic accumulation of fibroblasts in pulmonary fibrosis appears to depend on their invasion through basement membranes and extracellular matrices. Fibroblasts from the fibrotic lungs of patients with idiopathic pulmonary fibrosis (IPF) have been demonstrated to acquire a phenotype characterized by increased cell-autonomous invasion. Here, we investigated whether fibroblast invasion is further stimulated by soluble mediators induced by lung injury. We found that bronchoalveolar lavage fluids from bleomycin-challenged mice or patients with IPF contain mediators that dramatically increase the matrix invasion of primary lung fibroblasts. Further characterization of this non-cell-autonomous fibroblast invasion suggested that the mediators driving this process are produced locally after lung injury and are preferentially produced by fibrogenic (e.g., bleomycin-induced) rather than nonfibrogenic (e.g., LPS-induced) lung injury. Comparison of invasion and migration induced by a series of fibroblast-active mediators indicated that these two forms of fibroblast movement are directed by distinct sets of stimuli. Finally, knockdown of multiple different membrane receptors, including platelet-derived growth factor receptor-β, lysophosphatidic acid 1, epidermal growth factor receptor, and fibroblast growth factor receptor 2, mitigated the non-cell-autonomous fibroblast invasion induced by bronchoalveolar lavage from bleomycin-injured mice, suggesting that multiple different mediators drive fibroblast invasion in pulmonary fibrosis. The magnitude of this mediator-driven fibroblast invasion suggests that its inhibition could be a novel therapeutic strategy for pulmonary fibrosis. Further elaboration of the molecular mechanisms that drive non-cell-autonomous fibroblast invasion consequently may provide a rich set of novel drug targets for the treatment of IPF and other fibrotic lung diseases.

Indexed as

AnimalsBleomycinBronchoalveolar Lavage FluidCell MovementChemotaxisFibroblastsGene Knockdown TechniquesHumansIdiopathic Pulmonary FibrosisLipopolysaccharidesLung InjuryMaleMice, Inbred C57BLSolubilityTransforming Growth Factor betaBleomycinLipopolysaccharidesTransforming Growth Factor betafibroblastidiopathic pulmonary fibrosisinvasionmigrationpathogenesis

Identifiers

PMID26600305
PMCPMC4942213
OpenAlexW2177540623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.